Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases

Annals of Surgical Oncology

Volumn 23, Issue 4, 2016, Pages 1309-1319

  Hughes, Marybeth S ^a   Zager, Jonathan ^b   Faries, Mark ^c   Alexander, H Richard ^d   Royal, Richard E ^e   Wood, Bradford ^f   Choi, Junsung ^b   McCluskey, Kevin ^g   Whitman, Eric ^h   Agarwala, Sanjiv ⁱ   Siskin, Gary ^j   Nutting, Charles ^k   Toomey, Mary Ann ^a   Webb, Carole ^a   Beresnev, Tatiana ^a   Pingpank, James F ^g,l  

^a NATIONAL CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h Atlantic Health   (United States)

ⁱ St Luke's Cancer Center   (United States)

^j Albany Medical School   (United States)

^k RIA Endovascular   (United States)

^l UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; MELPHALAN; MITOMYCIN; PACLITAXEL; TEMOZOLOMIDE; YTTRIUM 90; ANTINEOPLASTIC AGENT;

ACUTE CHOLECYSTITIS; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLIZATION; BALLOON CATHETER; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE MELANOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SAFETY; PEPTIC ULCER; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; EYE NEOPLASMS; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; MELANOMA; MIDDLE AGED; PATHOLOGY; PERFUSION; PROGNOSIS; REGIONAL PERFUSION; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EMBOLIZATION, THERAPEUTIC; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PERFUSION; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84947945370     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4968-3     Document Type: Article

References (29)

1. Karlen AI, Clark JJ, Wong LL. Two cases of partial hepatectomy for malignant melanoma. Hawaii J Med Public Health. 2012;71:92–6
2. Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond). 2012;26:1157–72
3. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol. 2004;11:290–7
4. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6:1230–44
5. Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343–9
6. Pereira PR, Odashiro AN, Lim LA, Miyamoto C, Blanco PL, Odashiro M, et al. Current and emerging treatment options for uveal melanoma. Clin Ophthalmol. 2013;7:1669–82
7. Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager J, et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014;109:434–9
8. Rashid OM, Sloot S, Zager JS. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2014;10:1355–64
9. Gomez D, Wetherill C, Cheong J, Jones L, Marshall E, Damato B, et al. The liverpool uveal melanoma liver metastases pathway: outcome following liver resection. J Surg Oncol. 2014;109:542–7
10. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93:1042–6
11. Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Interv Radiol. 2013;36:158–65
12. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011;196:468–73
13. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009;252:290–8
14. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26:5436–42
15. Agarwala SS, Eggermont AM, O’Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120:781–9
16. Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2011;7:1383–94
17. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–70
18. Olofsson R, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, et al. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. Ann Surg Oncol. 2014;21:466–72
19. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465–74
20. Yamamoto M, Zager JS. Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol. 2014;109:383–8
21. Paulsen IF, Chakera AH, Drejoe JB, Klyver H, Dahlstrøm K, Oturai P, et al. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma. Dan Med J. 2014;61:A4741
22. Steinman J, Ariyan C, Rafferty B, Brady MS. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol. 2014;109:405–9
23. Wong J, Chen YA, Fisher KJ, Beasley GM, Tyler DS, Zager JS. Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. Ann Surg Oncol. 2014;21:650–5
24. Beasley GM, Speicher P, Augustine CK, Dolber PC, Peterson BL, Sharma K, et al. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Ann Surg Oncol. 2015;22:287–94
25. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589–95
26. Foletto MC, Haas SE. Cutaneous melanoma: new advances in treatment. An Bras Dermatol. 2014;89:301–10
27. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23
28. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44
29. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41–8